Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL993612 | 0.87 | KMT2A (0.44) | KMT2AOPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL993278 | 0.76 | OPRM1 (0.36) | OPRM1OPRL1OPRD1OPRK1KCNN4 | |
| SCHEMBL3709505 | 0.72 | THRA (0.46) | KMT2ANPC1HPGDRAB9AMEN1 | |
| SCHEMBL960035 | 0.71 | SMN1; SMN2 (0.45) | KMT2ANPC1HPGDRAB9AMEN1 | |
| SCHEMBL3645623 | 0.70 | KMT2A (0.43) | KMT2ANPC1HPGDRAB9AMEN1 | |
| SCHEMBL11926984 | 0.69 | KMT2A (0.43) | KMT2AOPRM1OPRK1NPC1HPGD | |
| SCHEMBL959309 | 0.68 | MTNR1A (0.46) | KMT2ANPC1RAB9AMEN1ALDH1A1 | |
| SCHEMBL2542597 | 0.66 | KMT2A (0.54) | KMT2ANPC1HPGDRAB9AMEN1 | |
| SCHEMBL1847562 | 0.65 | KMT2A (0.46) | KMT2ANPC1RAB9AMEN1LMNA | |
| SCHEMBL12047463 | 0.65 | KMT2A (0.70) | KMT2ANPC1HPGDRAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927539-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927539-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927539-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120208804-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | VITAE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208804-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | VITAE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208804-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | VITAE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2440537-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | Vitae Pharmaceuticals, Inc. (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2011011123-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011123-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | VITAE PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208804-A1 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 BASED ON THE 1,3 -OXAZINAN- 2 -ONE STRUCTURE | HSD11B1, HSD11B2, HSD17B1 | KMT2A 3940/4885OPRM1 2975/4885OPRL1 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.